These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11396233)

  • 21. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
    Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
    Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.
    Pallud C; Guinebretiere JM; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2005; 25(2B):1433-40. PubMed ID: 15865102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
    Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Schippinger W; Dandachi N; Regitnig P; Hofmann G; Balic M; Neumann R; Samonigg H; Bauernhofer T
    Am J Clin Pathol; 2007 Oct; 128(4):630-7. PubMed ID: 17875515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
    Bethune-Volters A; Labroquere M; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2004; 24(2C):1083-9. PubMed ID: 15154627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
    J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.
    Dittadi R; Zancan M; Perasole A; Gion M
    Int J Biol Markers; 2001; 16(4):255-61. PubMed ID: 11820721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients.
    Gauchez AS; Ravanel N; Villemain D; Brand FX; Pasquier D; Payan R; Mousseau M
    Anticancer Res; 2008; 28(5B):3067-73. PubMed ID: 19031958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer.
    Joshi AS; Sharangpani GM; Porter K; Keyhani S; Morrison C; Basu AS; Gholap GA; Gholap AS; Barsky SH
    Cytometry A; 2007 May; 71(5):273-85. PubMed ID: 17323351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum HER-2 concentration in patients with primary breast cancer.
    Kong SY; Kang JH; Kwon Y; Kang HS; Chung KW; Kang SH; Lee DH; Ro J; Lee ES
    J Clin Pathol; 2006 Apr; 59(4):373-6. PubMed ID: 16461567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
    Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H
    Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
    Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
    Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.